Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 49 entries
Sorted by: Best Match Show Resources per page
Role of Urodynamic Study in Nocturnal Enuresis: Urodynamic Findings and Treatment Outcome Correlation in Children with Pharmacotherapy-resistant Monosymptomatic Nocturnal Enuresis or Severe Non-monosymptomatic Nocturnal Enuresis.

Lower urinary tract symptoms

Ryu DS, Lee HW, Kwak KW, Park KH, Baek M.
PMID: 26663546
Low Urin Tract Symptoms. 2014 May;6(2):88-93. doi: 10.1111/luts.12024. Epub 2013 Jun 18.

OBJECTIVES: This study aimed to determine whether or not a urodynamic study (UDS) is beneficial for management of pediatric nocturnal enuresis (NE), especially in pharmacoresistant monosymptomatic nocturnal enuresis (PRMNE) or severe non-monosymptomatic nocturnal enuresis (NMNE) patients.METHODS: Children with PRMNE...

Cite
Ryu DS, Lee HW, Kwak KW, et al. Role of Urodynamic Study in Nocturnal Enuresis: Urodynamic Findings and Treatment Outcome Correlation in Children with Pharmacotherapy-resistant Monosymptomatic Nocturnal Enuresis or Severe Non-monosymptomatic Nocturnal Enuresis. Low Urin Tract Symptoms. 2013;6(2):88-93doi: 10.1111/luts.12024.
Ryu, D. S., Lee, H. W., Kwak, K. W., Park, K. H., & Baek, M. (2014). Role of Urodynamic Study in Nocturnal Enuresis: Urodynamic Findings and Treatment Outcome Correlation in Children with Pharmacotherapy-resistant Monosymptomatic Nocturnal Enuresis or Severe Non-monosymptomatic Nocturnal Enuresis. Lower urinary tract symptoms, 6(2), 88-93. https://doi.org/10.1111/luts.12024
Ryu, Dong Soo, et al. "Role of Urodynamic Study in Nocturnal Enuresis: Urodynamic Findings and Treatment Outcome Correlation in Children with Pharmacotherapy-resistant Monosymptomatic Nocturnal Enuresis or Severe Non-monosymptomatic Nocturnal Enuresis." Lower urinary tract symptoms vol. 6,2 (2014): 88-93. doi: https://doi.org/10.1111/luts.12024
Ryu DS, Lee HW, Kwak KW, Park KH, Baek M. Role of Urodynamic Study in Nocturnal Enuresis: Urodynamic Findings and Treatment Outcome Correlation in Children with Pharmacotherapy-resistant Monosymptomatic Nocturnal Enuresis or Severe Non-monosymptomatic Nocturnal Enuresis. Low Urin Tract Symptoms. 2014 May;6(2):88-93. doi: 10.1111/luts.12024. Epub 2013 Jun 18. PMID: 26663546.
Copy Download .nbib Format: NLM
Associations between different measures of anticholinergic drug exposure and Barthel Index in older hospitalized patients.

Therapeutic advances in drug safety

Bostock CV, Soiza RL, Mangoni AA.
PMID: 25114784
Ther Adv Drug Saf. 2013 Dec;4(6):235-45. doi: 10.1177/2042098613500689.

OBJECTIVE: To compare associations between four measures of anticholinergic exposure (anticholinergic risk scale, ARS; anticholinergic drug burden, DBAC; number and use versus no use of anticholinergic drugs), Barthel Index (BI, physical function) and Abbreviated Mental Test (AMT, cognitive function)...

Cite
Bostock CV, Soiza RL, Mangoni AA. Associations between different measures of anticholinergic drug exposure and Barthel Index in older hospitalized patients. Ther Adv Drug Saf. 2013;4(6):235-45doi: 10.1177/2042098613500689.
Bostock, C. V., Soiza, R. L., & Mangoni, A. A. (2013). Associations between different measures of anticholinergic drug exposure and Barthel Index in older hospitalized patients. Therapeutic advances in drug safety, 4(6), 235-45. https://doi.org/10.1177/2042098613500689
Bostock, Clare V, et al. "Associations between different measures of anticholinergic drug exposure and Barthel Index in older hospitalized patients." Therapeutic advances in drug safety vol. 4,6 (2013): 235-45. doi: https://doi.org/10.1177/2042098613500689
Bostock CV, Soiza RL, Mangoni AA. Associations between different measures of anticholinergic drug exposure and Barthel Index in older hospitalized patients. Ther Adv Drug Saf. 2013 Dec;4(6):235-45. doi: 10.1177/2042098613500689. PMID: 25114784; PMCID: PMC4125311.
Copy Download .nbib Format: NLM
Differential effects of direct and indirectly acting cholinergic agonists on growth hormone release in man, and lack of effect on cortisol secretion.

Journal of neuroendocrinology

Casanueva FF, Villanueva L, Cordido F, Diaz Y, Cabranes JA, Spiegel R, Dieguez C.
PMID: 19210431
J Neuroendocrinol. 1989 Oct 01;1(5):379-82. doi: 10.1111/j.1365-2826.1989.tb00132.x.

Abstract Acetylcholine plays a key role in the modulation of growth hormone secretion. In fact, growth hormone release after provocative stimuli is blocked by muscarinic cholinergic antagonists, and conversely, indirect cholinergic agonists potentiate growth hormone secretion. To further understand...

Cite
Casanueva FF, Villanueva L, Cordido F, et al. Differential effects of direct and indirectly acting cholinergic agonists on growth hormone release in man, and lack of effect on cortisol secretion. J Neuroendocrinol. 1989;1(5):379-82doi: 10.1111/j.1365-2826.1989.tb00132.x.
Casanueva, F. F., Villanueva, L., Cordido, F., Diaz, Y., Cabranes, J. A., Spiegel, R., & Dieguez, C. (1989). Differential effects of direct and indirectly acting cholinergic agonists on growth hormone release in man, and lack of effect on cortisol secretion. Journal of neuroendocrinology, 1(5), 379-82. https://doi.org/10.1111/j.1365-2826.1989.tb00132.x
Casanueva, F F, et al. "Differential effects of direct and indirectly acting cholinergic agonists on growth hormone release in man, and lack of effect on cortisol secretion." Journal of neuroendocrinology vol. 1,5 (1989): 379-82. doi: https://doi.org/10.1111/j.1365-2826.1989.tb00132.x
Casanueva FF, Villanueva L, Cordido F, Diaz Y, Cabranes JA, Spiegel R, Dieguez C. Differential effects of direct and indirectly acting cholinergic agonists on growth hormone release in man, and lack of effect on cortisol secretion. J Neuroendocrinol. 1989 Oct 01;1(5):379-82. doi: 10.1111/j.1365-2826.1989.tb00132.x. PMID: 19210431.
Copy Download .nbib Format: NLM
Efficacy of anticholinergics for chronic prostatitis/chronic pelvic pain syndrome in young and middle-aged patients: a single-blinded, prospective, multi-center study.

International neurourology journal

Kim DS, Kyung YS, Woo SH, Chang YS, Kim HJ.
PMID: 22087427
Int Neurourol J. 2011 Sep;15(3):172-5. doi: 10.5213/inj.2011.15.3.172. Epub 2011 Sep 30.

PURPOSE: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) exhibits variable lower urinary tract symptoms (LUTS). The aim of this study was to evaluate the incidence of LUTS and the efficacy of an anticholinergic agent in young and middle-aged CP/CPPS patients.METHODS:...

Cite
Kim DS, Kyung YS, Woo SH, et al. Efficacy of anticholinergics for chronic prostatitis/chronic pelvic pain syndrome in young and middle-aged patients: a single-blinded, prospective, multi-center study. Int Neurourol J. 2011;15(3):172-5doi: 10.5213/inj.2011.15.3.172.
Kim, D. S., Kyung, Y. S., Woo, S. H., Chang, Y. S., & Kim, H. J. (2011). Efficacy of anticholinergics for chronic prostatitis/chronic pelvic pain syndrome in young and middle-aged patients: a single-blinded, prospective, multi-center study. International neurourology journal, 15(3), 172-5. https://doi.org/10.5213/inj.2011.15.3.172
Kim, Doo Sang, et al. "Efficacy of anticholinergics for chronic prostatitis/chronic pelvic pain syndrome in young and middle-aged patients: a single-blinded, prospective, multi-center study." International neurourology journal vol. 15,3 (2011): 172-5. doi: https://doi.org/10.5213/inj.2011.15.3.172
Kim DS, Kyung YS, Woo SH, Chang YS, Kim HJ. Efficacy of anticholinergics for chronic prostatitis/chronic pelvic pain syndrome in young and middle-aged patients: a single-blinded, prospective, multi-center study. Int Neurourol J. 2011 Sep;15(3):172-5. doi: 10.5213/inj.2011.15.3.172. Epub 2011 Sep 30. PMID: 22087427; PMCID: PMC3212592.
Copy Download .nbib Format: NLM
Potentially inappropriate prescriptions of antipsychotic and anticholinergic drugs in patients with Parkinson's disease.

Neurodegenerative disease management

Valladales-Restrepo LF, Peña-Verjan NM, Vargas-Díaz K, Machado-Alba JE.
PMID: 34525848
Neurodegener Dis Manag. 2021 Oct;11(5):361-371. doi: 10.2217/nmt-2021-0021. Epub 2021 Sep 16.

No abstract available.

Cite
Valladales-Restrepo LF, Peña-Verjan NM, Vargas-Díaz K, et al. Potentially inappropriate prescriptions of antipsychotic and anticholinergic drugs in patients with Parkinson's disease. Neurodegener Dis Manag. 2021;11(5):361-371doi: 10.2217/nmt-2021-0021.
Valladales-Restrepo, L. F., Peña-Verjan, N. M., Vargas-Díaz, K., & Machado-Alba, J. E. (2021). Potentially inappropriate prescriptions of antipsychotic and anticholinergic drugs in patients with Parkinson's disease. Neurodegenerative disease management, 11(5), 361-371. https://doi.org/10.2217/nmt-2021-0021
Valladales-Restrepo, Luis Fernando, et al. "Potentially inappropriate prescriptions of antipsychotic and anticholinergic drugs in patients with Parkinson's disease." Neurodegenerative disease management vol. 11,5 (2021): 361-371. doi: https://doi.org/10.2217/nmt-2021-0021
Valladales-Restrepo LF, Peña-Verjan NM, Vargas-Díaz K, Machado-Alba JE. Potentially inappropriate prescriptions of antipsychotic and anticholinergic drugs in patients with Parkinson's disease. Neurodegener Dis Manag. 2021 Oct;11(5):361-371. doi: 10.2217/nmt-2021-0021. Epub 2021 Sep 16. PMID: 34525848.
Copy Download .nbib Format: NLM
Cognitive Function and Urologic Medications for Lower Urinary Tract Symptoms.

International neurourology journal

Kim YJ, Tae BS, Bae JH.
PMID: 33017894
Int Neurourol J. 2020 Sep;24(3):231-240. doi: 10.5213/inj.2040082.041. Epub 2020 Sep 30.

Special considerations should be made when selecting medications for the treatment of lower urinary tract symptoms (LUTS) in older patients especially those over 65 years old. This review summarizes the relationship between current treatments for LUTS and cognitive impairment....

Cite
Kim YJ, Tae BS, Bae JH. Cognitive Function and Urologic Medications for Lower Urinary Tract Symptoms. Int Neurourol J. 2020;24(3):231-240doi: 10.5213/inj.2040082.041.
Kim, Y. J., Tae, B. S., & Bae, J. H. (2020). Cognitive Function and Urologic Medications for Lower Urinary Tract Symptoms. International neurourology journal, 24(3), 231-240. https://doi.org/10.5213/inj.2040082.041
Kim, Yeon Joo, et al. "Cognitive Function and Urologic Medications for Lower Urinary Tract Symptoms." International neurourology journal vol. 24,3 (2020): 231-240. doi: https://doi.org/10.5213/inj.2040082.041
Kim YJ, Tae BS, Bae JH. Cognitive Function and Urologic Medications for Lower Urinary Tract Symptoms. Int Neurourol J. 2020 Sep;24(3):231-240. doi: 10.5213/inj.2040082.041. Epub 2020 Sep 30. PMID: 33017894; PMCID: PMC7538292.
Copy Download .nbib Format: NLM
Interactions of fluorescent cholinergic antagonists with the membrane-bound acetylcholine receptor.

Neurochemistry international

Tan YP, Stender W, Harvey AL, Soria B, Barrantes FJ.
PMID: 20487792
Neurochem Int. 1980;2:257-67. doi: 10.1016/0197-0186(80)90033-9.

The synthesis of pyrenyl-choline derivatives is reported. The interactions of these compounds with the acetylcholine receptor has been studied in developing chick myotubes in culture and in the adult frog neuromuscular junction with electrophysiological techniques. In vivo, the compounds...

Cite
Tan YP, Stender W, Harvey AL, et al. Interactions of fluorescent cholinergic antagonists with the membrane-bound acetylcholine receptor. Neurochem Int. 1980;2:257-67doi: 10.1016/0197-0186(80)90033-9.
Tan, Y. P., Stender, W., Harvey, A. L., Soria, B., & Barrantes, F. J. (1980). Interactions of fluorescent cholinergic antagonists with the membrane-bound acetylcholine receptor. Neurochemistry international, 2257-67. https://doi.org/10.1016/0197-0186(80)90033-9
Tan, Y P, et al. "Interactions of fluorescent cholinergic antagonists with the membrane-bound acetylcholine receptor." Neurochemistry international vol. 2 (1980): 257-67. doi: https://doi.org/10.1016/0197-0186(80)90033-9
Tan YP, Stender W, Harvey AL, Soria B, Barrantes FJ. Interactions of fluorescent cholinergic antagonists with the membrane-bound acetylcholine receptor. Neurochem Int. 1980;2:257-67. doi: 10.1016/0197-0186(80)90033-9. PMID: 20487792.
Copy Download .nbib Format: NLM
Stent Position Is More Important than α-Blockers or Anticholinergics for Stent-Related Lower Urinary Tract Symptoms after Ureteroscopic Ureterolithotomy: A Prospective Randomized Study.

Korean journal of urology

Lee SJ, Yoo C, Oh CY, Lee YS, Cho ST, Lee SH, Yang DY, Lee SK, Cho JS.
PMID: 20856649
Korean J Urol. 2010 Sep;51(9):636-41. doi: 10.4111/kju.2010.51.9.636. Epub 2010 Sep 16.

PURPOSE: To evaluate the clinical factors that impact ureteral stent-related lower urinary tract symptoms (LUTS) after ureteroscopic ureterolithotomy, including the stent position and medication.MATERIALS AND METHODS: Fifty-three patients who underwent ureteroscopic ureterolithotomy with indwelling a stent were distributed into...

Cite
Lee SJ, Yoo C, Oh CY, et al. Stent Position Is More Important than α-Blockers or Anticholinergics for Stent-Related Lower Urinary Tract Symptoms after Ureteroscopic Ureterolithotomy: A Prospective Randomized Study. Korean J Urol. 2010;51(9):636-41doi: 10.4111/kju.2010.51.9.636.
Lee, S. J., Yoo, C., Oh, C. Y., Lee, Y. S., Cho, S. T., Lee, S. H., Yang, D. Y., Lee, S. K., & Cho, J. S. (2010). Stent Position Is More Important than α-Blockers or Anticholinergics for Stent-Related Lower Urinary Tract Symptoms after Ureteroscopic Ureterolithotomy: A Prospective Randomized Study. Korean journal of urology, 51(9), 636-41. https://doi.org/10.4111/kju.2010.51.9.636
Lee, Sun Ju, et al. "Stent Position Is More Important than α-Blockers or Anticholinergics for Stent-Related Lower Urinary Tract Symptoms after Ureteroscopic Ureterolithotomy: A Prospective Randomized Study." Korean journal of urology vol. 51,9 (2010): 636-41. doi: https://doi.org/10.4111/kju.2010.51.9.636
Lee SJ, Yoo C, Oh CY, Lee YS, Cho ST, Lee SH, Yang DY, Lee SK, Cho JS. Stent Position Is More Important than α-Blockers or Anticholinergics for Stent-Related Lower Urinary Tract Symptoms after Ureteroscopic Ureterolithotomy: A Prospective Randomized Study. Korean J Urol. 2010 Sep;51(9):636-41. doi: 10.4111/kju.2010.51.9.636. Epub 2010 Sep 16. PMID: 20856649; PMCID: PMC2941813.
Copy Download .nbib Format: NLM
Duration of Antimuscarinic Administration for Treatment of Overactive Bladder Before Which One Can Assess Efficacy: An Analysis of Predictive Factors.

International neurourology journal

Hsiao SM, Liao CH, Lin HH, Kuo HC.
PMID: 26620899
Int Neurourol J. 2015 Sep;19(3):171-7. doi: 10.5213/inj.2015.19.3.171. Epub 2015 Sep 22.

PURPOSE: To determine the duration of antimuscarinic therapy for overactive bladder syndrome (OAB) appropriate for assessment of the efficacy of treatment, and to evaluate the possible predictive factors for response to therapy.METHODS: All OAB patients who visited a urology...

Cite
Hsiao SM, Liao CH, Lin HH, et al. Duration of Antimuscarinic Administration for Treatment of Overactive Bladder Before Which One Can Assess Efficacy: An Analysis of Predictive Factors. Int Neurourol J. 2015;19(3):171-7doi: 10.5213/inj.2015.19.3.171.
Hsiao, S. M., Liao, C. H., Lin, H. H., & Kuo, H. C. (2015). Duration of Antimuscarinic Administration for Treatment of Overactive Bladder Before Which One Can Assess Efficacy: An Analysis of Predictive Factors. International neurourology journal, 19(3), 171-7. https://doi.org/10.5213/inj.2015.19.3.171
Hsiao, Sheng-Mou, et al. "Duration of Antimuscarinic Administration for Treatment of Overactive Bladder Before Which One Can Assess Efficacy: An Analysis of Predictive Factors." International neurourology journal vol. 19,3 (2015): 171-7. doi: https://doi.org/10.5213/inj.2015.19.3.171
Hsiao SM, Liao CH, Lin HH, Kuo HC. Duration of Antimuscarinic Administration for Treatment of Overactive Bladder Before Which One Can Assess Efficacy: An Analysis of Predictive Factors. Int Neurourol J. 2015 Sep;19(3):171-7. doi: 10.5213/inj.2015.19.3.171. Epub 2015 Sep 22. PMID: 26620899; PMCID: PMC4582089.
Copy Download .nbib Format: NLM
Efficacy and safety of low-dose anticholinergics to treat men with lower urinary tract symptoms with overactive bladder: a retrospective study based on real life practice.

Prostate international

Park KK, Lee SH, Chung BH, Kim SJ, Kwak C, Son HC, Kim SW, Lee JY.
PMID: 24223400
Prostate Int. 2013;1(1):37-41. doi: 10.12954/PI.12005. Epub 2013 Feb 02.

PURPOSE: To investigate whether combination treatment using an α-blocker and 2 mg of tolterodine could improve the International Prostate Symptom Score (IPSS) as much as α-blocker and 4 mg of tolterodine without voiding difficulties in real life practice.METHODS: We...

Cite
Park KK, Lee SH, Chung BH, et al. Efficacy and safety of low-dose anticholinergics to treat men with lower urinary tract symptoms with overactive bladder: a retrospective study based on real life practice. Prostate Int. 2013;1(1):37-41doi: 10.12954/PI.12005.
Park, K. K., Lee, S. H., Chung, B. H., Kim, S. J., Kwak, C., Son, H. C., Kim, S. W., & Lee, J. Y. (2013). Efficacy and safety of low-dose anticholinergics to treat men with lower urinary tract symptoms with overactive bladder: a retrospective study based on real life practice. Prostate international, 1(1), 37-41. https://doi.org/10.12954/PI.12005
Park, Kyung Kgi, et al. "Efficacy and safety of low-dose anticholinergics to treat men with lower urinary tract symptoms with overactive bladder: a retrospective study based on real life practice." Prostate international vol. 1,1 (2013): 37-41. doi: https://doi.org/10.12954/PI.12005
Park KK, Lee SH, Chung BH, Kim SJ, Kwak C, Son HC, Kim SW, Lee JY. Efficacy and safety of low-dose anticholinergics to treat men with lower urinary tract symptoms with overactive bladder: a retrospective study based on real life practice. Prostate Int. 2013;1(1):37-41. doi: 10.12954/PI.12005. Epub 2013 Feb 02. PMID: 24223400; PMCID: PMC3821520.
Copy Download .nbib Format: NLM
Muscarinic receptors control markers of inflammation in the small intestine of BALB/c mice.

Journal of neuroimmunology

Arciniega-Martínez IM, Pacheco-Yépez J, Santamaria-Chávez MM, Rebollar-Ruíz XA, Cárdenas-Jaramillo LM, Jarillo-Luna RA, Campos-Rodríguez R, Drago-Serrano ME, Reséndiz-Albor AA.
PMID: 34823118
J Neuroimmunol. 2022 Jan 15;362:577764. doi: 10.1016/j.jneuroim.2021.577764. Epub 2021 Nov 09.

Muscarinic-acetylcholine-receptors (mAChRs) modulate intestinal homeostasis, but their role in inflammation is unclear; thus, this issue was the focus of this study. BALB/c mice were treated for 7 days with muscarine (mAChR/agonist), atropine (mAChR/antagonist) or saline. Small-intestine samples were collected...

Cite
Arciniega-Martínez IM, Pacheco-Yépez J, Santamaria-Chávez MM, et al. Muscarinic receptors control markers of inflammation in the small intestine of BALB/c mice. J Neuroimmunol. 2021;362:577764doi: 10.1016/j.jneuroim.2021.577764.
Arciniega-Martínez, I. M., Pacheco-Yépez, J., Santamaria-Chávez, M. M., Rebollar-Ruíz, X. A., Cárdenas-Jaramillo, L. M., Jarillo-Luna, R. A., Campos-Rodríguez, R., Drago-Serrano, M. E., & Reséndiz-Albor, A. A. (2022). Muscarinic receptors control markers of inflammation in the small intestine of BALB/c mice. Journal of neuroimmunology, 362577764. https://doi.org/10.1016/j.jneuroim.2021.577764
Arciniega-Martínez, Ivonne Maciel, et al. "Muscarinic receptors control markers of inflammation in the small intestine of BALB/c mice." Journal of neuroimmunology vol. 362 (2022): 577764. doi: https://doi.org/10.1016/j.jneuroim.2021.577764
Arciniega-Martínez IM, Pacheco-Yépez J, Santamaria-Chávez MM, Rebollar-Ruíz XA, Cárdenas-Jaramillo LM, Jarillo-Luna RA, Campos-Rodríguez R, Drago-Serrano ME, Reséndiz-Albor AA. Muscarinic receptors control markers of inflammation in the small intestine of BALB/c mice. J Neuroimmunol. 2022 Jan 15;362:577764. doi: 10.1016/j.jneuroim.2021.577764. Epub 2021 Nov 09. PMID: 34823118.
Copy Download .nbib Format: NLM
Comparative associations between anticholinergic burden and emergency department visits for anticholinergic adverse events in older Korean adults: a nested case-control study using national claims data for validation of a novel country-specific scale.

BMC pharmacology & toxicology

Hwang S, Chung JE, Jun K, Ah YM, Kim KI, Lee JY.
PMID: 33413627
BMC Pharmacol Toxicol. 2021 Jan 07;22(1):2. doi: 10.1186/s40360-020-00467-6.

BACKGROUND: Considering the limited generalizability of previous anticholinergic burden scales, the Korean Anticholinergic Burden Scale (KABS) as a scale specific to the Korean population was developed. We aimed to validate the KABS by detecting the associations between high anticholinergic...

Cite
Hwang S, Chung JE, Jun K, et al. Comparative associations between anticholinergic burden and emergency department visits for anticholinergic adverse events in older Korean adults: a nested case-control study using national claims data for validation of a novel country-specific scale. BMC Pharmacol Toxicol. 2021;22(1):2doi: 10.1186/s40360-020-00467-6.
Hwang, S., Chung, J. E., Jun, K., Ah, Y. M., Kim, K. I., & Lee, J. Y. (2021). Comparative associations between anticholinergic burden and emergency department visits for anticholinergic adverse events in older Korean adults: a nested case-control study using national claims data for validation of a novel country-specific scale. BMC pharmacology & toxicology, 22(1), 2. https://doi.org/10.1186/s40360-020-00467-6
Hwang, Sunghee, et al. "Comparative associations between anticholinergic burden and emergency department visits for anticholinergic adverse events in older Korean adults: a nested case-control study using national claims data for validation of a novel country-specific scale." BMC pharmacology & toxicology vol. 22,1 (2021): 2. doi: https://doi.org/10.1186/s40360-020-00467-6
Hwang S, Chung JE, Jun K, Ah YM, Kim KI, Lee JY. Comparative associations between anticholinergic burden and emergency department visits for anticholinergic adverse events in older Korean adults: a nested case-control study using national claims data for validation of a novel country-specific scale. BMC Pharmacol Toxicol. 2021 Jan 07;22(1):2. doi: 10.1186/s40360-020-00467-6. PMID: 33413627; PMCID: PMC7792041.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 49 entries